Evidence map›Paper›PMID 30179249›Full record

ArticleFEBS letters2018

Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4.

Josiah Ochieng, Gladys Nangami, Amos Sakwe, Tanu Rana, Shalonda Ingram, Jeffrey S Goodwin, Cierra Moye, Philip Lammers, Samuel E Adunyah

Open access · bronzeAbstract read
In one paragraph

Article in FEBS letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Extra-nuclear histones: origin, significance and perspectives.Molecular and cellular biochemistry · 2022
    Review
  13. Article
  14. Review
  15. In Vitro Biocompatibility Assessment of Nano-Hydroxyapatite.Nanomaterials (Basel, Switzerland) · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Josiah OchiengDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Gladys NangamiDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Amos SakweDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Tanu RanaDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Shalonda IngramDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Jeffrey S GoodwinDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Cierra MoyeDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Philip LammersDepartment of Internal Medicine, Meharry Medical College, Nashville, TN, USA.
Samuel E AdunyahDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA.
Meharry Medical College · US

Funding

The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Maureen Sanderson · 2017 to 2026
$48.2M
Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
THE MEHARRY RISE INITIATIVER25GM059994 · NIGMS · MEHARRY MEDICAL COLLEGE · PI MOTLEY-JOHNSON, EVANGELINE D · 1999 to 2021
$23.0M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2011 to 2025
$18.8M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Role of Fetuin-A in Tumor Cell GrowthSC1CA134018 · NCI · MEHARRY MEDICAL COLLEGE · PI OCHIENG, JOSIAH · 2007 to 2012
$1.7M
NCI NIH HHS K12 CA090625NCI NIH HHS SC1 CA134018NCI NIH HHS U54 CA163069NIGMS NIH HHS R25 GM059994NIMHD NIH HHS U54 MD007586NIMHD NIH HHS U54 MD007593
6 · The paper itself

Abstract

The mechanisms by which exosomes (nano-vesicular messengers of cells) are taken up by recipient cells are poorly understood. We hypothesized that histones associated with these nanoparticles are the ligands which facilitate their interaction with cell surface syndecan-4 (SDC4) to mediate their uptake. We show that the incubation with fetuin-A (exosome-associated proteins) and histones mediates the uptake of exosomes that are normally not endocytosed. Similarly, hydroxyapatite-nanoparticles incubated with fetuin-A and histones (FNH) are internalized by tumor cells, while nanoparticles incubated with fetuin-A alone (FN) are not. The uptake of exosomes and FNH, both of which move to the perinuclear region of the cell, is attenuated in SDC4-knockdown cells. Data show that FNH can compete with exosomes for uptake and that both use SDC4 as uptake receptors.

Indexed as

alpha-2-HS-GlycoproteinCell Line, TumorCell MembraneDurapatiteEndocytosisExosomesExtracellular SpaceHistonesHumansLigandsMicroscopy, ConfocalNanoparticlesNeoplasmsPC-3 CellsRNA InterferenceSyndecan-4AHSG protein, humanalpha-2-HS-GlycoproteinDurapatiteHistonesLigandsSyndecan-4exosomeshistoneshydroxyapatitenanoparticles and syndecan-4

Identifiers

PMID30179249
PMCPMC6188801
OpenAlexW2890189115

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.